William B. Capra

1.8k citations

20 papers · 1.0k indexed · 1 hit paper · h-index 13

Co-authors: Brandon Arnieri Hans‐Georg Müller Michael D. Taylor Samuel Whipple Gillis Carrigan Michael W. Lu Sandra D. Griffith Ryan Copping
Topics: Statistical Methods in Clinical Trials (7 papers)Lung Cancer Treatments and Mutations (5 papers)Cancer Genomics and Diagnostics (4 papers)
Cited by: Virology Health Informatics Statistics and Probability
Journals: Nature Proceedings of the National Academy of Sciences JAMA
Partner nations: United States Switzerland Japan

In The Last Decade

William B. Capra

20 papers receiving 980 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluating eligibility criteria of oncology trials using real-world data and AI

2021 184 citations Ruishan Liu, Shemra Rizzo et al. Nature profile →

Peers

Countries citing papers authored by William B. Capra

Since Specialization

Citations

This map shows the geographic impact of William B. Capra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William B. Capra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William B. Capra more than expected).

Fields of papers citing papers by William B. Capra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William B. Capra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William B. Capra. The network helps show where William B. Capra may publish in the future.

Co-authorship network of co-authors of William B. Capra

This figure shows the co-authorship network connecting the top 25 collaborators of William B. Capra. A scholar is included among the top collaborators of William B. Capra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William B. Capra. William B. Capra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations 2022 ·Contemporary Clinical Trials Communications ·(unknown),(unknown),Melissa D. Curtis,Shrujal S. Baxi,William B. Capra,Elizabeth Garrett‐Mayer,Brian P. Hobbs,David S. Hong,Rebecca A. Hubbard,Jiawen Zhu,Somnath Sarkar,Meghna Samant	10
2	External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges 2022 ·Current Epidemiology Reports ·Gillis Carrigan,Brian D. Bradbury,M. Alan Brookhart,William B. Capra,Victoria Chia,Kenneth J. Rothman,Khaled Sarsour,Michael D. Taylor,(unknown)	10
3	Evaluating eligibility criteria of oncology trials using real-world data and AIbreakdown → 2021 ·Nature ·Ruishan Liu,Shemra Rizzo,Samuel Whipple,Navdeep Pal,Arturo López Pineda,Michael W. Lu,Brandon Arnieri,Ying Lü,William B. Capra,Ryan Copping,James Zou	184
4	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data 2021 ·Clinical Pharmacology & Therapeutics ·(unknown),(unknown),(unknown),(unknown),(unknown),Melisa Tucker,Aracelis Z. Torres,(unknown),William B. Capra,Melissa D. Curtis,Rebecca A. Miksad	19
5	Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials 2019 ·Clinical Pharmacology & Therapeutics ·Gillis Carrigan,Samuel Whipple,William B. Capra,Michael D. Taylor,Jeffrey S. Brown,Michael W. Lu,Brandon Arnieri,Ryan Copping,Kenneth J. Rothman	72
6	An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database 2019 ·Pharmacoepidemiology and Drug Safety ·Gillis Carrigan,Samuel Whipple,Michael D. Taylor,Aracelis Z. Torres,Anala Gossai,Brandon Arnieri,Melisa Tucker,(unknown),Peter Lambert,Sandra D. Griffith,William B. Capra	43
7	Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set 2019 ·JCO Clinical Cancer Informatics ·Sandra D. Griffith,Rebecca A. Miksad,(unknown),Paul You,(unknown),Ariel B. Bourla,Erin Williams,Daniel J. George,Deborah Schrag,Sean Khozin,William B. Capra,Michael D. Taylor,Amy P. Abernethy	76
8	P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients 2018 ·Journal of Thoracic Oncology ·Fabrice Barlési,Luis Paz‐Ares,Damian R. Page,Ashwini Shewade,Peter Lambert,Tariq I. Mughal,(unknown),(unknown),Brandon Arnieri,William B. Capra,Stefan Foser,Céline Mascaux,Lukas Bubendorf,(unknown)	1
9	Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint 2018 ·Health Services Research ·Melissa D. Curtis,Sandra D. Griffith,Melisa Tucker,Michael D. Taylor,William B. Capra,Gillis Carrigan,(unknown),Aracelis Z. Torres,Paul You,Brandon Arnieri,Amy P. Abernethy	166
10	Characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving molecular diagnostic (MD) testing in U.S. routine clinical practice. 2017 ·Journal of Clinical Oncology ·(unknown),Ashwini Shewade,Peter Lambert,Brandon Arnieri,William B. Capra,(unknown),Tariq I. Mughal,Laurie M. Gay,Damian R. Page,Stefan Foser	1
11	Long-term follow up of a double-blind, randomized, placebo-controlled trial of Cyclosporine Inhalation Solution (CyIS) in lung transplant recipients 2005 ·The Journal of Heart and Lung Transplantation ·Aldo Iacono,William B. Capra,Stephen B. Shrewsbury,B. A. Johnson,Wayne F. Grgurich,Timothy E. Corcoran,J.G. Youssef,(unknown),Gerald C. Smaldone,Adriana Zeevi,Samuel A. Yousem,John J. Fung,James H. Dauber,Gilbert J. Burckart,Bartley P. Griffith,Kenneth R. McCurry	1
12	A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors 2005 ·Molecular Cancer Therapeutics ·David Weng,(unknown),Susan F. Radka,(unknown),(unknown),Ram Ganapathi,Paul Elson,William B. Capra,Vann P. Parker,Jennifer A. Lockridge,J. Wayne Cowens,Nassim Usman,Ernest C. Borden	52
13	Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints 2004 ·Controlled Clinical Trials ·William B. Capra	14
14	Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease 2000 ·The Journal of Infectious Diseases ·Sean Emery,William B. Capra,David A. Cooper,Ronald T. Mitsuyasu,Joseph A. Kovacs,Pamela Vig,Mary Smolskis,Louis D. Saravolatz,H. Clifford Lane,Gwen Fyfe,Peter Curtin,(unknown)	86
15	Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy 2000 ·JAMA ·Richard T. Davey,Robert L. Murphy,Francesco Graziano,Steven Boswell,Andrew T. Pavia,(unknown),Jeffrey P. Nadler,Doreen Chaitt,Robin Dewar,David Sahner,(unknown),William B. Capra,Wai Yie Leong,Martin Giedlin,H. Clifford Lane,James O. Kahn	138
16	Viral load in treatment with antiretroviral therapy and interleukin 2 2000 ·PubMed ·Richard T. Davey,William B. Capra	3
17	Analysis of oldest-old mortality: lifetables revisited 1998 ·The Annals of Statistics ·Jane-Ling Wang,Hans‐Georg Müller,William B. Capra	42
18	An Accelerated-Time Model for Response Curves 1997 ·Journal of the American Statistical Association ·William B. Capra,Hans‐Georg Müller	33
19	An Accelerated-Time Model for Response Curves 1997 ·Journal of the American Statistical Association ·William B. Capra,Hans‐Georg Müller	6
20	Early mortality surge in protein-deprived females causes reversal of sex differential of life expectancy in Mediterranean fruit flies 1997 ·Proceedings of the National Academy of Sciences ·(unknown),Jane-Ling Wang,William B. Capra,Pablo Liedo,James R. Carey	54

About William B. Capra

William B. Capra is a scholar working on Statistics and Probability, Virology and Aging, having authored 20 papers that have together received 1.0k indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Genomics and Diagnostics (4 papers). The work is most often cited by research in Virology (189 citations), Health Informatics (46 citations) and Statistics and Probability (204 citations). William B. Capra has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include Brandon Arnieri, Hans‐Georg Müller, Michael D. Taylor, Samuel Whipple, Gillis Carrigan, Michael W. Lu, Sandra D. Griffith, Ryan Copping, Aracelis Z. Torres and Paul You. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact